217 results about "Tumour therapy" patented technology

In a method for diagnosis and treatment of a patient with a tumor relating to prostate cancer, the following steps are implemented. A differential diagnosis of prostate cancer versus prostatitis and / or BPH is conducted on a patient using a cost-effective diagnosis method. If prostate cancer is diagnosed in the patient using a cost-effective measurement method, a characteristic value for the tumor aggressiveness of the prostate cancer is determined. A watchful waiting treatment is implemented with the patient given a characteristic value below a predeterminable first limit value. The size and position of the tumor is determined using a cost-effective method given a characteristic value above the first limit value. A cost-effective ultrasonic theranosis or a conventional therapy is conducted for a size below a second predeterminable limit value. The presence of metastases in the patient is checked, with a cost-intensive method generating image information, for a size above the second limit value. A metastasis treatment is implemented in the event that metastases are present. In the event that no metastases are present, a tumor treatment based on the aforementioned image information generated is implemented.

The invention relates to an injection anticancer long circulating targeting liposome which is characterized in that anti-angiogenic drug is combined with anticancer drug, the liposome modified by polypeptide with tumor targeting function and hydrophilic polyethyleneglycol is adopted for loading and transporting the two drugs to tumor positions, and the tumor curative effect is enhanced through the different releasing rates and action mechanism of the two drugs.

The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of an amatoxin and a target-binding moiety, e.g. an antibody, connected by certain linkages, which are useful in the treatment of cancer and other disorders and diseases. In a further aspect the invention relates to pharmaceutical compositions comprising such conjugates.

The invention relates to a somatostatin receptor-mediated tumor targeted pharmaceutical composition which adopts a targeted somatostatin receptor functional polypeptide and polyethylene glycol for simultaneously modifying a pharmaceutical carrier, and an anti-tumor drug or / and an anti-angiogenic drug is delivered to the tumor part, thereby enhancing the tumor treatment effect.

The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of a toxin and a target-binding moiety, e.g. an antibody, which are useful in the treatment of cancer. In particular, the toxin is an amatoxin, and the target-binding moiety is preferably directed against tumour-associated antigens. In particular, the amatoxin is conjugated to the antibody by linker moieties. In particular the linker moieties are covalently bound to functional groups located in positions of the amatoxin proved as preferred positions for the attachment of linkers with respect to optimum antitumor activity. In a further aspect the invention relates to pharmaceutical compositions comprising such target-binding moiety toxin conjugates and to the use of such target-binding moiety toxin conjugates for the preparation of such pharmaceutical compositions. The target-binding moiety toxin conjugates and pharmaceutical compositions of the invention are useful for the treatment of cancer.

The invention discloses a tumor-targeting drug delivery system, and the system comprises a tumor-targeting drug carrier and a tumor-treating drug, wherein the tumor-targeting drug carrier comprises full heavy-chain human ferritin. The invention also discloses a preparation method for the tumor-treating drug delivery system. The method comprises: depolymerizing polymerized full heavy-chain human ferritin; adding the tumor-treating drug into the depolymerized full heavy-chain human ferritin, so as to enable depolymerized full heavy-chain human ferritin to be combined with the tumor-treating drug; and polymerizing the depolymerized full heavy-chain human ferritin combined with the tumor-treating drug again to form nano-particles.

The invention relates to the technical field of biology and in particular relates to a specific target polypeptide self-assembled nanoparticle. The nanoparticle is prepared from a hydrophobic anti-tumor drug with a therapeutic dosage and an amphipathic polypeptide which covers the periphery of the hydrophobic anti-tumor drug through a self-assembling manner, wherein the amphipathic polypeptide is a target peptide which can be used for specifically targeting a epidermal growth factor receptor of a tumor cell; a terminal N of the target peptide is coupled with a hydrophobic functional molecule. After the nanoparticle targets the tumor cell, the target peptide is exposed; the nanoparticle targets the tumor cell and enters the tumor cell through receptor-mediated endocytosis, and the drug is released to inhibit DNA (Deoxyribonucleic Acid) synthesis and repairing; the nanoparticle has dual killing effects on the tumor cells and the growth of the tumor cell is inhibited. The amphipathic polypeptide does not generate a covalent bond in a self-assembling process and no reverse reaction is caused; the specific target polypeptide self-assembled nanoparticle is used for treating tumors and has the advantages of no toxin and good biocompatibility.

A comprehensive localized therapy method and equipment for tumor features that various endoscopes are used to inject the magnetic immune microspheres carrying biologic medicine and the antineoplastic magnetic chemical medicine into tumor focus, the liquid radioactive source is poured in the inner cavity of catheter, and an alternative magnetic field is generated around the tumor focus to induce the microspheres to generate heat and adsorbing the antineoplastic medicine to round the tumor focus. Its advantage is the combination of biotherapy, chemicotherapy, radiotherapy and thermotherapy.

The invention relates to a genetically modified mesenchymal stem cell (MSC) and medical use thereof in the treatment of tumours, said MSC comprising one or more exogenous nucleic acid molecule(s), wherein said exogenous nucleic acid molecule(s) comprise a region encoding one or more immune response-stimulating or immune response-modulating cytokine(s) operably linked to a promoter or promoter / enhancer combination. The invention encompasses the use of said cells in modulating the tumour microenvironment in order to attract immune effector cells and facilitate their activation and / or adoption of a memory phenotype. One aspect of the invention relates to the use of said cells in anti-tumour treatment comprising the combined administration of said mesenchymal stem cells with anti-tumour immunotherapies, such as checkpoint inhibitors, immune cells, for example T cells, such as T cells with artificial T cell receptors, for example a chimeric antigen receptor (CAR-Ts) or exogenous T-Cell Receptor (TCR) transduced cells, NK cells or macrophages / monocytes, or a cancer vaccine.

Brachytherapy radioisotope carrier systems and methodology for providing real-time customized brachytherapy treatment to subjects with tumors difficult to control using conventional radiation therapy techniques. The invention generally relates to devices, methods and kits for providing customized radionuclide treatments, to help cure, slow progression or regrowth, or ameliorate the symptoms associated with tumors.

The invention belongs to the technical field of nano-medicines, and discloses a photosensitive type cell membrane biomimetic targeting nanodrug for tumor combined therapy and a preparation method thereof. According to the nanodrug and the preparation method thereof, a human O-type red blood cell membrane is used as a carrying platform, albumin is used as a drug carrier, DACHPt is used as a chemotherapeutic drug, ICG is used as a photosensitive reagent, RGD is used as a targeting molecule, so that a biomimetic drug carrying system with biomimetic characteristic and high drug loading capacity and capable of being specifically targeted at tumor cells and realizing synergistic anti-tumor sensitization is prepared, the novel biomimetic drug carrying system not only can realize efficient carrying of the drug, but also can effectively prolong the in-vivo circulation time, so that accurate and continuous drug administration at the position of a focus of a tumor is realized, the defect of tumordrug administration can be efficiently overcome through the biomimetic effect of the drug, and a drug carrying and administration and targeted therapy synergistic working mechanism is formed; and thepurpose of tumor chemotherapy and photo-thermal therapy multi-mechanism combined tumor treatment is achieved, and a new idea and platform are provided for tumor treatment.

The invention relates to a device and a method for treating tumors through irreversible electroporation, belonging to the technical field of tumor treatment. The device mainly comprises a square wave pulse generation and measurement system, a signal conversion system, a man-machine communication system, a measurement control system and a power supply system. In the method, the device and a therapeutic electrode are used for treating the tumors through a program. Under the circumstance of no injection of chemotherapeutic drugs, microsecond square wave pulses are applied to tumor tissues, the entire tumor cell is fully damaged, so that the tumor cell dies due to irreversible electroporation, and the harm on the body of a patient caused by the side effect of the chemotherapeutic drugs is radically avoided. The invention has the characteristics of short treatment time, no pain, good treatment effect, high safety, convenient use, simple operation, convenient popularization and application and the like. The device and the method can be widely used for treating the tumors of human and animals, and are especially applicable to human tumor treatment.

Brachytherapy radioisotope carrier systems and methodology for providing real-time customized brachytherapy treatment to subjects with tumors difficult to control using conventional radiation therapy techniques. The invention generally relates to devices, methods and kits for providing customized radionuclide treatments, to help cure, slow progression or regrowth, or ameliorate the symptoms associated with tumors.

The invention provides a novel radionuclide labelled somatostatin analogue molecular probe and its application and belongs to the field of radiopharmaceuticals labelling and nuclear medicine technologies. A bifunctional chelator couples cyclic polypeptide Pasireotide, and then radionuclide is used for labelling so as to obtain a radionuclide labelled neuroendocrine neoplasm specific somatostatin analogue radioactive molecular probe. The molecular probe can be combined with a tumor expression somatostatin receptor (SSTR), and SSTR positive tumor tissue can be accurately positioned by means of nuclear medicine. Thus, the purpose of disease target molecular imaging diagnosis and treatment is achieved. The synthesized molecular probe has higher affinity and functional activity for SSTR and is expected to become a somatostatin analogue developer and tumor therapeutic agent with a good prospect.

The invention relates to a method for increasing medicament carrying amount and entrapment rate of polymer micelles on an anti-tumor medicament by using hydrophobic molecules. The polymer micelles are prepared from amphipathilic polymer such as polyethylene glycol-phosphatidyl ethanolamine (PEG-DSPE) by a membrane hydration method, and the micelles can be used for wrapping insoluble or low water-soluble anti-tumor medicaments for chemotherapy of tumor. Compared with the polymer micelles prepared without adding hydrophobic molecules, the polymer micelles obtained by adding the hydrophobic molecules such as phospholipid molecules with longer aliphatic chains (10 to 20 carbon atoms) in a certain proportion during preparing the polymer micelles by using the membrane hydration method obviously increase the entrapment rate and the medicament carrying amount on the raw material medicaments of the anti-tumor medicaments. The entrapment rate increment of the polymer micelles on the raw material medicaments improves the utilization rate of the raw material medicaments, and the medicament carrying amount of the polymer micelles improves the efficiency of medicament transmission during treating the tumor so as to lay a foundation for further increasing the curative effect of the anti-tumor medicament.

The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of a toxin and a target-binding moiety, e.g. an antibody, which are useful in the treatment of cancer. In particular, the toxin is an amatoxin, and the target-binding moiety is preferably directed against tumour-associated antigens. In particular, the amatoxin is conjugated to the antibody by linker moieties. In particular the linker moieties are covalently bound to functional groups located in positions of the amatoxin proved as preferred positions for the attachment of linkers with respect to optimum antitumor activity. In a further aspect the invention relates to pharmaceutical compositions comprising such target-binding moiety toxin conjugates and to the use of such target-binding moiety toxin conjugates for the preparation of such pharmaceutical compositions. The target-binding moiety toxin conjugates and pharmaceutical compositions of the invention are useful for the treatment of cancer.

Antibodies which bind to activated members of the erbB, TNF, and IgSF family of receptors and pharmaceutical compositions comprising the same are disclosed. Peptides and mimetics of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are also described. Methods of using such antibodies, peptides, and mimetics in tumor therapeutic, prophylactic, imaging and diagnostic applications are disclosed.

The present invention is tumor treating steep pulse equipment and process, and belongs to the field of tumor treating technology. The tumor treating steep pulse equipment includes one steep pulse generating, measuring and controlling system, one computer system, one power source system, and one control console. The tumor treating steep pulse equipment with tumor treating electrodes is used for program tumor treatment, and ns level steep pulse is applied to the tumor tissue, so as to destroy and kill tumor cell irreversibly through electric shock. The present invention has high treatment effect, no side effect caused by chemotherapeutic medicine and simple operation, and may be used widely for the tumor treatment of human body and animal.

Disclosed are methods and compositions for inhibiting the growth of a tumor (e.g., a malignant tumor) in a subject. In particular, combination therapies for treating a tumor in a subject by co-administering either i) an effective amount of an anti-estrogen agent or ii) an effective amount of a receptor tyrosine kinase inhibitor and an effective amount of a bispecific anti-ErbB2 / anti-ErbB3 antibody, and optionally an effective amount trastuzumab. Also disclosed is a bispecific anti-ErbB2 / anti-ErbB3 antibody for use in the therapy of a tumor in combination with either i) an anti-estrogen agent or ii) a receptor tyrosine kinase inhibitor, and optionally in use with trastuzumab.

The invention discloses a targeting mesoporous polydopamine multi-purpose nanometer diagnosis and treatment preparation as well as a preparation method and applications of the targeting mesoporous polydopamine multi-purpose nanometer diagnosis and treatment preparation. The targeting mesoporous polydopamine multi-purse nanometer diagnosis and treatment preparation is composed of a water-soluble folic-acid-targeting mesoporous polydopamine medicine carrier, hydrophobic regorafenib and manganese sulfate, wherein the mass ratio of regorafenib to the folic-acid-targeting mesoporous polydopamine medicine carrier is (0.5-4): 1, and the mass ratio of manganese sulfate to the folic-acid-targeting mesoporous polydopamine medicine carrier is (1-6):1. The targeting mesoporous polydopamine diagnosis and treatment preparation can recognize positive tumor cells of a folic acid receptor, so that a targeting effect is achieved during treatment. For the diagnosis and treatment preparation, the chemotherapy under the guidance of MRI imaging is realized, the tumor treatment effect is expected to be improved, meanwhile, the biocompatibility is good, and therefore, the targeting mesoporous polydopaminemulti-purpose nanometer diagnosis and treatment preparation has the clinical application potential.

A system and method for therapy and diagnosis of a human or animal. At least one coupling element for coupling of radiation couples radiation from at least a first radiation source to a tumour site and / or from said second radiation source to said site and / or from said site to a detector. The coupling elements are combinations of at least one translatory distributor, at least one rotary distributor, and at least one operation mode selector means for directing either said therapeutic radiation or said diagnostic radiation to said site through said at least one first radiation conductor. The system may be used for interactive interstitial photodynamic tumour therapy. The system and method according to the invention combines the advantages of purely mechanical and purely non-mechanical solutions in a new and synergetic way.

The invention relates to an anti-tumor drug compound and application thereof. The compound includes a glutaminase inhibitor and a tumor angiogenesis inhibitor which are used together with each other. The invention especially provides the glutaminase inhibitor as shown as formula (I) listed in a specification. The glutaminase inhibitor has an obvious inhibiting effect for glutaminase activity. The inhibition for the growth of the tumor strain can reach up to 90% or above under the condition that the dosage of the drug combination is only 1 / 5 of the dosage of singly used drugs, the generation of the bloods surrounding human tumors and the transfer of the tumors are obviously restrained and the corresponding side effect of the drug combination is much lower than that of single drug, so that the drug combination of the glutaminase inhibitor and the tumor angiogenesis inhibitor at a certain ratio is effective in treating tumors and the drug combination compared with the single drug has an obvious synergic effect and is an efficient low-toxicity antitumor drug combination.

The invention belongs to the field of biomedical polymer materials, and specifically relates to a thermally induced hydrogel containing selenium or tellurium, and a preparation method and applications thereof. The thermally induced hydrogel is composed of an amphiphilic block copolymer containing selenium or tellurium and a solvent; thermally induced gelatinization phase transformation of a water system of the amphiphilic block copolymer and the solvent can be realized with temperature increasing so as to realize spontaneous formation of a physical hydrogel, wherein the amphiphilic block copolymer containing selenium or tellurium is obtained via covalent bonding of small molecules containing selenium or tellurium with an amphiphilic block copolymer. Long-acting platinum drug gel sustained-release preparations can be obtained via coordination of the thermally induced hydrogel with platinum drugs. The long-acting platinum drug gel sustained-release preparations are capable of prolonging and adjusting release behavior of the loaded platinum antitumor drugs. Drug administration of the long-acting platinum drug gel sustained-release preparations in tumor, around tumor, or in tumor cavity can be realized via injection; in situ formation of gel is realized at body temperature, and the platinum drugs loaded via coordination bonds can be released from the gel slowly, so that administration frequency is reduced, and drug whole body toxicity is reduced. The long-acting platinum drug gel sustained-release preparations can be applied to tumor treatment at different periods.

The present invention relates generally to a cell culture process and to cells produced therefrom. More particularly, the present invention provides a method of supporting dendritic cell viability, proliferation and / or differentiation. The dendritic cells of the present invention are useful, inter alia, in the immunotherapy of cancer, infectious disease, autoimmunity and tumour therapy and as adjuvants, immune system modulating agents, immunotherapeutic agents and tolerising agents.

The invention discloses antitumor platinum drug mineralization protein nanoparticles and a preparation method and application thereof. The antitumor platinum drug mineralization protein nanoparticlesand the preparation method thereof have the advantages that the platinum drug mineralization protein nanoparticles are successfully prepared through the two-step preparation method for the first time,the prepared nanoparticles can be uniformly dispersed in an aqueous solution, the nanoparticles has good cytotoxicity, and the IC50 of the nanoparticles to human non-small-cell lung cancer cells A549is 6.9 microgram / ml; the platinum drug mineralization protein nanoparticles comprising a platinum drug and protein are simple in preparation process, uniform in size, controllable in particle size, good in biocompatibility, good in water solubility, long in blood circulation time, high in tumor targeting performance and capable of laying a foundation for efficient tumor treatment or drug-resistant tumor treatment.

The invention relates to a medicine for treating tumor and hemorrhoid and a manufacturing method thereof. The medicine aims at the disadvantages that: the prior treatment method for removing the hemorrhoid and the tumor can only kill or remove partial tumor cells, has large pain and high recurrence rate during the treatment period, has the phenomena of lassitude, hypodynamia, nausea, vomiting and hemogram reduction during the radiotherapy period, causes low immunity, damages self-immunologic function of a human body, inhibits functions of bone marrow stem cells, is easy to produce drug dependence, and is easy for recurrence. The invention prepares tannic acid, atropine, gallic acid, quinin hydrochloride, ferrous sulfate, caffeine, pure sulfuric acid, urethane, carbolic acid, sterile water and the like, into medicines for local parts of pathological changes, does not hurt normal tissues, has no pain, does not need to treat for a long time, and has the advantages of taking effect by injecting at one time, no recurrence, wide raw materials, low cost, wide clinical application, and small side effect.

The invention discloses an acid-responsive nanometer micelle for drug loading, a preparation method and an application thereof. The nano-micelles were self-assembled from hydrophilic segment polyethylene glycol (PEG) and hydrophobic segment pH-sensitive polyaspartyl diisopropylethylenediamine / di-n-butylethylenediamine (PAsp (DIP / DBA)). The nano-micelles can prolong the drug circulation time, aggregate in the tumor site, increase the local drug concentration, and respond to the micro-acid environment of the tumor tissue. As a drug carrier of stimulation response, the nano-micelles can rapidly release the loaded chemotherapeutic drug adriamycin in the tumor site, and play a significant anti-tumor effect. At the same time, the nano-micelles loaded with magnetic resonance contrast agent superparamagnetic iron oxide can be used for tumor magnetic resonance imaging and monitoring drug uptake and aggregation. This method utilizes nano-drug aggregation at tumor site and acid responsiveness ofcarrier to realize rapid drug release to improve tumor therapeutic effect, and endows nano-micellar MRI visualization function, which provides a promising innovative strategy for cancer diagnosis andtreatment, and has broad application prospects.

A medical image diagnosis apparatus and an image data processing apparatus that diagnoses vascular invasion status of a tumor and decides the most appropriate therapy method for the tumor by extracting tumor candidate regions and vascular regions based on extensive volume data derived from covering a therapy target organ, and specifying an adjacent vascular region existing within a prescribed scope from a gravity center of a tumor. The tumor candidate regions and vascular regions are generated as 3D image data or MPR image data for submitting a recommended therapy method for the tumor by adding branch data of the adjacent vascular.

The invention relates to a method for preparing individually-customized pelvic tumor prosthesis. The method comprises the following steps of: reconstructing three-dimensional models of pelvises and tumors according to two-dimensional images of captive tests (CT), magnatic resonance imaging (MRI) and the like of patients before operations, demarcating a tumor excision boundary according to a tumor therapeutic principle, and determining a plane and an angle of pelvic osteotomy; and reconstructing the three-dimensional models of amputated pelvic defect parts by comparing with normal pelvises, designing and producing individually-customized prosthesis, and performing surface modification on a contacting section of a prosthesis material and bones to fulfill the aim of combining the prosthesis material and the bones stably. The pelvic tumor prosthesis designed by the method can be customized individually aiming at the tumor excision range of different patients to retain bone mass as far as possible while the tumors are excised completely, and can be matched with the original pelvic excision parts accurately to realize accurate pelvic reconstruction operations; bone integration is formed between the prosthesis and the bones to ensure the long-term stability of the prosthesis; and hip joints of the prosthesis are designed by super-radium acetabuli, so the prosthesis is stable and has a motion function.